NCT02028572 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Ajtony C, Balla Z, Somoskeoy S, Kovacs B
Relationship between visual field sensitivity and retinal nerve fiber layer thickness as measured by optical coherence tomography. Invest Ophthalmol Vis Sci. 2007 Jan;48(1):258-63.
El Beltagi TA, Bowd C, Boden C, Amini P, Sample PA, Zangwill LM, Weinreb RN
Retinal nerve fiber layer thickness measured with optical coherence tomography is related to visual function in glaucomatous eyes. Ophthalmology. 2003 Nov;110(11):2185-91.
Hood DC, Kardon RH
A framework for comparing structural and functional measures of glaucomatous damage. Prog Retin Eye Res. 2007 Nov;26(6):688-710. Epub 2007 Aug 21. Review.

A Cross Sectional Study of Correlation Between Retinal Nerve Fibre Thickness Measured by Optical Coherence Tomography and Humphrey Visual Fields in Early and Moderate Open Angle Glaucoma

Details for clinical trial NCT02028572

Clinical trial NCT02028572 - References